Fromkin Andrew J.
SEC Form 4 insider trading activity
Fromkin Andrew J. has filed 3 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: May 29, 2026.
On the most recent filing, Fromkin Andrew J. is listed as Director at Immunovant, Inc. Inside the rolling window, Fromkin Andrew J. reported no open-market purchases and 2 open-market sales totaling $8.0M in IMVT. The largest disclosed transaction in the window is a sale of 221,951 IMVT shares on May 28, 2026, worth $7.4M.
Companies traded
Other insiders at IMVT
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$8.0M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Fromkin Andrew J. made?
Fromkin Andrew J. has filed 3 SEC Form 4 filings (9 transaction rows) across 1 company since 2025.
Which companies does Fromkin Andrew J. trade?
Fromkin Andrew J. has filed SEC Form 4 disclosures for 1 company, including IMVT.
When was Fromkin Andrew J.'s most recent SEC Form 4 filing?
Fromkin Andrew J.'s most recent SEC Form 4 filing on Tracefour is dated May 29, 2026.
What is Fromkin Andrew J.'s total buy and sell value in the current window?
Inside the rolling retention window, Fromkin Andrew J. bought $0 and sold $8.0M based on SEC Form 4 filings.
What was Fromkin Andrew J.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 221,951 IMVT shares on 2026-05-28, worth $7.4M, per SEC Form 4 filings.